- Report
- April 2026
- 160 Pages
Global
From €2972EUR$3,320USD£2,552GBP
€3715EUR$4,150USD£3,190GBP
- Report
- April 2026
- 313 Pages
North America
From €5367EUR$5,995USD£4,608GBP
- Report
- April 2026
- 260 Pages
Asia Pacific
From €5367EUR$5,995USD£4,608GBP
- Report
- August 2025
- 197 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- August 2025
- 183 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- April 2026
- 102 Pages
Canada
From €4472EUR$4,995USD£3,839GBP

Ventricular Tachycardia (VT) is a type of cardiac arrhythmia that is characterized by an abnormally fast heart rate originating from the ventricles of the heart. It is a potentially life-threatening condition that can lead to cardiac arrest and sudden death. Treatment for VT typically involves the use of antiarrhythmic drugs, catheter ablation, and implantable cardioverter-defibrillators (ICDs).
The VT market is a subset of the larger cardiology market, which is composed of a variety of products and services used to diagnose and treat cardiovascular diseases. This includes medical devices, pharmaceuticals, and services such as cardiac imaging, cardiac rehabilitation, and electrophysiology.
Companies in the VT market include Medtronic, Abbott, Boston Scientific, Biotronik, and St. Jude Medical. These companies produce a variety of products and services related to VT, such as ICDs, pacemakers, catheters, and ablation systems. Show Less Read more